Abstract: The present invention concerns the product produced by inactivating extracellular or intracellular pathogenic virus in a biological composition without incurring substantial disruption or inactivation of cells and without significant loss of labile proteins or other valuable biological components also contained therein, the inactivation process comprising subjecting said composition to a virucidally effective amount of irradiation in the presence of (a) a mixture of a compound that quenches type I photodynamic reactions and a compound that quenches type II photodynamic reactions or (b) a bifunctional compound that is capable of quenching both type I and type II reactions, to thereby inactivate said virus while retaining functionality of said composition. The composition is advantageously subjected to the irradiation and the mixture of compounds or bifunctional compound in the presence of an irradiation sensitizer.

Abstract: The present invention concerns the product produced by inactivating extracellular or intracellular pathogenic virus in a biological composition without incurring substantial disruption or inactivation of cells and without significant loss of labile proteins or other valuable biological components also contained therein, the inactivation process comprising subjecting said composition to a virucidally effective amount of irradiation in the presence of (a) a mixture of a compound that quenches type I photodynamic reactions and a compound that quenches type II photodynamic reactions or (b) a bifunctional compound that is capable of quenching both type I and type II reactions, to thereby inactivate said virus while retaining functionality of said composition. The composition is advantageously subjected to the irradiation and the mixture of compounds or bifunctional compound in the presence of an irradiation sensitizer.

Abstract: The present invention concerns a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition containing ≧1×109 cells/ml by contacting that composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and oxygen and/or a quencher. In one embodiment of the invention, the process is conducted under conditions whereby a structural integrity of greater than 80% of at least one type of blood cell contained within said composition is retained.

Abstract: The present invention concerns the product produced by inactivating extracellular or intracellular pathogenic virus in a biological composition without incurring substantial disruption or inactivation of cells and without significant loss of labile proteins or other valuable biological components also contained therein, the inactivation process comprising subjecting said composition to a virucidally effective amount of irradiation in the presence of (a) a mixture of a compound that quenches type I photodynamic reactions and a compound that quenches type II photodynamic reactions or (b) a bifunctional compound that is capable of quenching both type I and type II reactions, to thereby inactivate said virus while retaining functionality of said composition. The composition is advantageously subjected to the irradiation and the mixture of compounds or bifunctional compound in the presence of an irradiation sensitizer.

Abstract: The present invention concerns the product produced by inactivating extracellular or intracellular pathogenic virus in a biological composition without incurring substantial disruption or inactivation of cells and without significant loss of labile proteins or other valuable biological components also contained therein, the inactivation process comprising subjecting said composition to a virucidally effective amount of irradiation in the presence of (a) a mixture of a compound that quenches type I photodynamic reactions and a compound that quenches type II photodynamic reactions or (b) a bifunctional compound that is capable of quenching both type I and type II reactions, to thereby inactivate said virus while retaining functionality of said composition. The composition is advantageously subjected to the irradiation and the mixture of compounds or bifunctional compound in the presence of an irradiation sensitizer.

Abstract: A process is presented for transfusing cells which have been sterilized with radiation and a quencher of type I and type II photodynamic reactions. The cells are removed from a donor and exposed to virucidally effective amount of radiation in the presence of a quencher of type I and type II reactions, or a mixture of a quencher for type I reactions and a quencher of type II reactions. Subsequently, the sterilized cell containing fraction is returned to the donor.

Abstract: The present invention concerns the product produced by inactivating extracellular lipid enveloped pathogenic virus or intracellular pathogenic virus in a composition containing >1.times.10.sup.9 cells/ml and said virus without incurring substantial disruption or inactivation of such cells, the inactivation process comprising contacting the composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer, thereby substantially to inactivate the virus with retention of cell functionality, greater than 80%. The present invention also concerns the product produced by inactivating virus in a biological composition without incurring substantial disruption or inactivation thereof, the inactivation process comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound, light, and a quencher thereby to inactivate said virus while retaining functionality of said substance.

Abstract: The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10.sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of .gtoreq.1.times.10.sup.9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.

Abstract: A process of inactivating infectious viruses in a cell-containing or a protein-containing composition containing such viruses, comprising contacting such composition with an effective amount of at least one aryl diol epoxide of the formula ##STR1## in which X is an aromatic ring system having from 3 to 6 used rings,for a sufficient period of time substantially to inactivate said viruses without incurring substantial disruption or inactivation of cells or without incurring substantial protein denaturation.